http://www.scripintelligence.com/therapysector/cns/ CNS RSS en-us ℗ & © 2013 of Informa Pharma. Please refer to the Terms and Conditions of Use at http://www.scripintelligence.com rss@scripintelligence.com (scripintelligence) CNS artUrl TSRI professor Franck Polleux led a study with research associate Georges Mairet-Coello that identified inhibition of the AMP-activated kinase (AMPK) and the upstream calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) as potential Alzheimer's... Mon, 10 Jun 2013 07:35:00 +0100 http://www.scripintelligence.com/home/Scripps-researchers-ID-potential-Alzheimers-drug-target-343877 artUrl The institute dispensed with any preliminary draft guidance for the drug and went straight to final draft guidance because the drug is recommended in line with its licensed indication. Fri, 07 Jun 2013 08:20:01 +0100 http://www.scripintelligence.com/home/OtsukaLundbecks-Abilify-gets-NICE-thumbs-up-for-bipolar-adolescents-343848 artUrl Tue, 04 Jun 2013 08:56:34 +0100 http://www.scripintelligence.com/home/ASCO-Clovis-stock-doubles-on-possible-breakthrough-lung-cancer-drug-343721 artUrl At the end of a three-day meeting last week in Washington, high-ranking US government officials joined patient groups and academic leaders advocating for greater Alzheimer's disease research and better strategies for drug development in declaring that... Mon, 03 Jun 2013 19:13:00 +0100 http://www.scripintelligence.com/home/US-Capitol-Capsule-Allies-offer-Alzheimers-advice-Combo-attack-343691 artUrl The European Union has agreed to withdraw all oral almitrine treatments from the market due to concerns that the drug causes nerve damage in the hands and feet. Fri, 31 May 2013 17:20:00 +0100 http://www.scripintelligence.com/policyregulation/EU-withdraws-Serviers-almitrine-343677 artUrl Out of a total of 19 corporate acquisition or financing deals completed in Asia over the April 2012-March 2013 period, it comes as no surprise to see Asia's largest homegrown pharma firm, Japan's Takeda, take home the prize for sheer number of... Mon, 03 Jun 2013 10:20:07 +0100 http://www.scripintelligence.com/home/Takeda-leads-Asias-acquisitive-charge-in-201213-343684 artUrl After all, said Guggenheim Securities analyst Dr Bret Holley, there already was a high likelihood of US approval of asfotase alfa based on positive Phase II results, which demonstrated a 90% response rate in the primary bone healing endpoint. Wed, 29 May 2013 01:35:00 +0100 http://www.scripintelligence.com/policyregulation/Unsurprising-FDA-breakthrough-designation-for-Alexions-hypophosphatasia-drug-343564 artUrl If it wasn't clear that investor demand for US biotechnology initial public offerings has returned, consider the evidence: two companies registered first-time offerings, two set price ranges and two launched IPOs during the past week. Mon, 27 May 2013 18:35:00 +0100 http://www.scripintelligence.com/home/Institutional-investors-fuel-burgeoning-biotech-IPO-market-343530 artUrl New York-based Forest's stock closed up 5.4% at $39.53 per share on the news that, effective 31 December, Mr Solomon will step down as president and CEO. He will remain chairman until Forest's 2014 Annual General Meeting (AGM) and retain the title of... Fri, 24 May 2013 06:20:00 +0100 http://www.scripintelligence.com/home/Forest-investors-upbeat-as-CEO-Solomon-retires-343491 artUrl Companies could see lower prices take effect sooner and potential delays to launch if German policy makers do way with the 12 month grace period of free pricing for new drugs before the outcome of the AMNOG benefit assessments and pricing talks kick in,... Wed, 05 Jun 2013 15:05:04 +0100 http://www.scripintelligence.com/home/German-Sativex-pricing-saga-could-end-free-pricing-holiday-343771 artUrl I'm also pretty sure he would not mind being characterized as an unusual senior executive within big pharma in Japan (and maybe elsewhere) - highly animated, passionate and willing to look at challenges from an unconventional angle. Tue, 28 May 2013 03:05:00 +0100 http://www.scripintelligence.com/home/INTERVIEW-Maverick-Otsuka-looks-to-challenge-the-norm-343537 artUrl But the advisers split on the company’s proposal to market the drug at higher dose levels. In a vote of 8-7, the panel decided that the drug carried too many serious side effects to be marketed with recommended prescriptions of 30 and 40 milligrams... Thu, 23 May 2013 04:50:00 +0100 http://www.scripintelligence.com/home/Merck-gets-nod-from-US-panel-on-sleeping-pill-but-safety-flagged-343454 artUrl US FDA staff said in documents for a May 22 advisory committee meeting that Merck’s drug suvorexant appears to work but poses safety issues such as suicidal thoughts and daytime drowsiness in doses tested by the company. Panelists at the meeting... Tue, 21 May 2013 03:20:00 +0100 http://www.scripintelligence.com/home/Merck-faces-tough-questions-about-sleeping-pill-343385 artUrl Santa Clara, California-based XenoPort had already suspended development of the drug in gastro-esophageal reflux disease (GERD) back in 2011 after a Phase IIb trial also failed to show statistically significant efficacy. The candidate is a prodrug of the... Mon, 20 May 2013 16:20:00 +0100 http://www.scripintelligence.com/researchdevelopment/XenoPort-drops-MS-spasticity-drug-after-PhIII-flop-343367 artUrl Indeed, having Medicare cover Amyvid would ensure broader patient access for the radioactive diagnostic agent, which is used in Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adults with... Fri, 17 May 2013 17:59:00 +0100 http://www.scripintelligence.com/home/Lilly-to-CMS-Failure-to-cover-Amyvid-will-chill-Alzheimers-RandD-343302 artUrl Seattle Genetics President and CEO Dr Clay Siegall said the company's goal is to broaden the US labeling claims of the drug to provide patients and physicians the opportunity to incorporate the ADC into additional HL and sALCL treatment settings. Wed, 15 May 2013 06:20:00 +0100 http://www.scripintelligence.com/policyregulation/FDA-accepts-Adcetris-sBLA-for-expanded-HL-ALCL-use-343187 artUrl The drug is the first IL-1 beta approved in the US for SJIA and also is the first medicine specifically OK'd by the FDA as a monthly subcutaneous injection for the disease, which affects 5-15 children per 100,000 in the US and is the most severe subtype... Mon, 13 May 2013 11:37:00 +0100 http://www.scripintelligence.com/policyregulation/Novartis-Ilaris-gains-FDA-OK-in-rare-childhood-arthritis-343091 artUrl The deal was announced nearly five months after US FDA approval for the drug, which is administered by Alexza's Staccato device to treat agitation in adults with bipolar I disorder or schizophrenia in hospital settings. Thu, 09 May 2013 05:35:01 +0100 http://www.scripintelligence.com/business/Alexza-partners-with-Teva-for-US-Adasuve-launch-342944 artUrl Concordia, a wholly owned subsidiary of Concordia Healthcare, has acquired the US rights to three products. Kapvay (extended release clonidine) is an alpha2-adrenergic agonist used for attention-deficit hyperactivity disorder, while Orapred ODT and... Thu, 09 May 2013 02:50:00 +0100 http://www.scripintelligence.com/business/Shionogi-divests-US-pediatrics-as-Osphena-takes-center-stage-342943 artUrl Nonetheless, Dr John Leonard, senior vice president and chief scientific officer at AbbVie, said winning the breakthrough therapy designation "reflects the potential of this regimen to be important in the treatment of HCV." Tue, 07 May 2013 06:35:00 +0100 http://www.scripintelligence.com/policyregulation/FDA-bestows-breakthrough-on-AbbVie-hep-C-combo-Scioderm-fragile-skin-therapy-342863